Incannex Healthcare

IXHLPhase 3

incannex.com.au

Incannex Healthcare is advancing a diversified portfolio of drug candidates that combine cannabinoids, psychedelics, and other novel compounds to address complex disorders with limited treatment options. The company has established a robust clinical development pathway with several programs in Phase 2 trials and strategic research collaborations. Incannex leverages its Australian base to access global markets through NASDAQ listing (IXHL) while pursuing FDA regulatory pathways for its most advanced candidates.

Market Cap

$41.8M

Employees

20-50

Focus

Biotech

IXHL · Stock Price

USD 2.991333.81 (-99.78%)

Historical price data

AI Company Overview

Technology Platform

Development of novel drug formulations combining cannabinoids and psychedelic compounds with established pharmaceuticals, focusing on synergistic effects for specific medical conditions.

Pipeline Snapshot

3 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
IHL-42X Low Dose + IHL-42X High Dose + Placebo + IHL-42X (Optimal Dose) + Dronab...	Obstructive Sleep Apnea	Phase 2/3
IHL-675A + Cannabidiol + Hydroxychloroquine + Placebo	Rheumatoid Arthritis	Phase 2
IHL42X + Acetazolamide 250 MG + Dronabinol 2.5 MG	Obstructive Sleep Apnea	Phase 1

Opportunities

Growing acceptance of psychedelic medicine creates expanding market opportunities.

Multiple shots on goal across different therapeutic areas increases probability of success.

Potential for breakthrough therapy designation and accelerated regulatory pathways for promising candidates.

Risk Factors

High clinical development risk inherent in novel drug candidates.

Regulatory complexity for Schedule I substances.

Capital intensive operations requiring continuous fundraising.

Competitive pressure from larger pharmaceutical companies entering the space.

Competitive Landscape

Competes in emerging psychedelic medicine space against COMPASS Pathways, MindMed, and Cybin, and in cannabinoid pharmaceuticals against Jazz Pharmaceuticals. Differentiation through combination therapies and focus on specific mechanistic applications rather than broad indications.